Human liver organoids for disease modeling of fibrolamellar carcinoma

Nicole J.C. Narayan, David Requena, Gadi Lalazar, Lavoisier Ramos-Espiritu, Denise Ng, Solomon Levin, Bassem Shebl, Ruisi Wang, William J. Hammond, James A. Saltsman, Helmuth Gehart, Michael S. Torbenson, Hans Clevers, Michael P. LaQuaglia, Sanford M. Simon

Research output: Contribution to journalArticlepeer-review


Fibrolamellar carcinoma (FLC) is a rare, often lethal, liver cancer affecting adolescents and young adults, for which there are no approved therapeutics. The development of therapeutics is hampered by a lack of in vitro models. Organoids have shown utility as a model system for studying many diseases. In this study, tumor tissue and the adjacent non-tumor liver were obtained at the time of surgery. The tissue was dissociated and grown as organoids. We developed 21 patient-derived organoid lines: 12 from metastases, three from the liver tumor and six from adjacent non-tumor liver. These patient-derived FLC organoids recapitulate the histologic morphology, immunohistochemistry, and transcriptome of the patient tumor. Patient-derived FLC organoids were used in a preliminary high-throughput drug screen to show proof of concept for the identification of therapeutics. This model system has the potential to improve our understanding of this rare cancer and holds significant promise for drug testing and development.

Original languageEnglish (US)
Pages (from-to)1874-1888
Number of pages15
JournalStem Cell Reports
Issue number8
StatePublished - Aug 9 2022


  • fibrolamellar
  • liver cancer
  • pediatric cancer

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Human liver organoids for disease modeling of fibrolamellar carcinoma'. Together they form a unique fingerprint.

Cite this